Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 36,64€ (+12,74%). La mediana è 36,06€ (+10,95%).
| Acquista |
22 |
| Mantieni |
20 |
| Vendi |
4 |
Notizie Vai al feed delle notizie
Teva asks judge to bar mention of Israeli origin at Humana price-fixing trial
Teva asked a U.S. judge to prevent insurer Humana from telling jurors the company is Israeli, arguing references to its national origin could prejudice the jury amid strong U.S. emotions over the Gaza war. The Tel Aviv-based drugmaker said national origin is irrelevant to allegations it conspired to inflate generic drug prices and could undermine a fair trial. The U.S. trial is scheduled to begin Sept. 15 and covers claims over drugs including baclofen and propranolol. » Altro su finance.yahoo.com
Teva Pharmaceutical jumps after Q2 revenue beat and plan for direct NYSE listing
Teva Pharmaceutical shares rose about 12% after its Q2 report where adjusted EPS missed estimates at $0.02 but revenue of $4.1 billion topped consensus and the revenue decline was milder than expected. The company reiterated full-year sales and adjusted EPS guidance slightly below analyst averages and said it will replace ADRs with newly listed common stock on the New York Stock Exchange, starting September 14. Investors welcomed the direct listing as a potential catalyst to attract institutional and retail demand. » Altro su finance.yahoo.com
Teva's turnaround gains momentum as duvakitug could spark major upside
Teva has shifted from generics toward branded drugs, with products like Austedo, Ajovy and Uzedy showing mid-double-digit sales growth and driving an 85% year‑to‑date share recovery. Management expects 2026 EPS to fall to $1.91–$2.11 largely due to the dilutive Emalex acquisition, but foresees operating profit and adjusted EBITDA rising next year aided by biosimilars and core drug growth. The key catalyst is duvakitug, co‑developed with Sanofi for ulcerative colitis and Crohn's disease; phase 3 success could lead to $2–5 billion in peak annual sales and potentially send the stock significantly higher, while shares currently trade below 10x estimated 2027 earnings. » Altro su finance.yahoo.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 3,63Mld | 2,43% |
| Utile lordo | 1,89Mld | 5,78% |
| Utile netto | −504,70M | 310,95% |
| EBITDA | −16,65M | 102,99% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 36,93Mld€ |
Numero di azioni | 1,16Mld |
Massimo/minimo a 52 settimane | 32,48€ - 15,30€ |
| Dividendi | No |
Beta | 0,88 |
Rapporto P/E | 57,77 |
Rapporto PEG | 0,10 |
Rapporto P/B | 5,56 |
Rapporto P/S | 2,47 |
Profilo aziendale
Teva Pharmaceutical Industries Limited, ein Pharmaunternehmen, entwickelt, produziert, vermarktet und vertreibt Generika, Spezialmedikamente und biopharmazeutische Produkte in Nordamerika, Europa und international. Das Unternehmen bietet sterile Produkte, Hormone, hochwirksame Medikamente und zytotoxische Substanzen in verschiedenen Darreichungsformen an, darunter Tabletten, Kapseln, Injektionsmittel, Inhalationsmittel, Flüssigkeiten, transdermale Pflaster, Salben und Cremes. Außerdem entwickelt, produziert und vertreibt das Unternehmen pharmazeutische Wirkstoffe. Darüber hinaus konzentriert sich das Unternehmen auf die Bereiche zentrales Nervensystem, Schmerzen, Atemwege und Onkologie. Zu den Produkten im Bereich des zentralen Nervensystems gehören Copaxone zur Behandlung schubförmiger Formen der Multiplen Sklerose, AJOVY zur vorbeugenden Behandlung von Migräne und AUSTEDO zur Behandlung von Spätdyskinesien und Chorea im Zusammenhang mit der Huntington-Krankheit. Die Produkte des Unternehmens auf dem Atemwegsmarkt umfassen ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler und ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax und AirDuo RespiClick/ArmonAir RespiClick für die Behandlung von Asthma und chronisch obstruktiven Lungenerkrankungen. Zu seinen Produkten auf dem Onkologiemarkt gehören Bendeka, Treanda, Granix, Trisenox, Lonquex und Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited kooperiert mit MedinCell bei der Entwicklung und Vermarktung mehrerer langwirksamer injizierbarer Produkte, einer Risperidon-Suspension für die Behandlung von Patienten mit Schizophrenie. Das Unternehmen wurde 1901 gegründet und hat seinen Hauptsitz in Tel Aviv-Yafo, Israel.
| Nome | Teva Pharmaceuticals |
| CEO | Richard D. Francis |
| Sede centrale | Tel Aviv,
ta Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 16/02/1982 |
| Dipendenti | 32.008 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | TEVA |
Frankfurt | TEV.F |
Düsseldorf | TEV.DU |
Hamburg | TEV.HM |
London | 0LER.L |
SIX | TEVA.SW |
München | TEV.MU |
Wien | TEVA.VI |
Scopri gli asset
Gli azionisti di Teva Pharmaceuticals investono anche nei seguenti asset
